Understanding how brain inflammation accelerates cognitive decline could reshape prevention strategies for the 55 million people worldwide living with dementia. While amyloid plaques and tau tangles have dominated Alzheimer's research for decades, mounting evidence positions chronic neuroinflammation as the critical bridge between protein pathology and actual memory loss.
This comprehensive analysis reveals that activated microglia and astrocytes don't merely respond to amyloid-beta accumulation—they actively amplify the damage cascade. These immune cells trigger inflammatory responses that worsen both amyloid deposition and tau hyperphosphorylation, creating a self-perpetuating cycle of neuronal destruction. The review synthesizes data showing how genetic mutations in APP, PSEN1, and PSEN2 alter protein processing, while APOE variants influence inflammatory susceptibility. Recent monoclonal antibody trials demonstrate this inflammatory connection: donanemab achieved 60% slower cognitive decline, suggesting that targeting amyloid pathology can interrupt the neuroinflammation feedback loop.
This inflammatory framework offers more actionable insights than purely genetic approaches. Unlike inherited mutations, neuroinflammation represents a modifiable target through lifestyle interventions, anti-inflammatory compounds, and emerging immunotherapies. The bidirectional relationship between protein pathology and immune activation suggests that early intervention—before extensive plaque formation—could prevent the inflammatory cascade that drives clinical symptoms. For health-conscious adults, this positions brain inflammation as a measurable biomarker and therapeutic target, shifting focus from inevitable genetic destiny toward preventable inflammatory processes that accelerate cognitive aging.